BofA/Merrill Lynch Downgrades Spero Therapeutics (SPRO) to Underperform
Get Alerts SPRO Hot Sheet
Price: $1.43 --0%
Rating Summary:
5 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 3
Rating Summary:
5 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 3
Join SI Premium – FREE
BofA/Merrill Lynch analyst Jason Gerberry downgraded Spero Therapeutics (NASDAQ: SPRO) from Neutral to Underperform with a price target of $9.00 (from $19.00).
The analyst list three reasons for the downgrade:
- SPR994 for the treatment of complicated urinary tract infections as more nich drug than prior analyst team,
- 55% probability-of-success reflecting the fact prior Phase 2 has limited read-through to '994's registration study due to protocol difference,
- early-stage antibiotic potentiator program is intriguing but unlikely to unlock meaningful value until program is validated in larger studies.
For an analyst ratings summary and ratings history on Spero Therapeutics click here. For more ratings news on Spero Therapeutics click here.
Shares of Spero Therapeutics closed at $9.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Hertz Global (HTZ) to Underperform
- Dover Corp. (DOV) PT Raised to $185 at Mizuho
- Morgan Stanley Downgrades Mobileye N.V (MBLY) to Underweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!